311 related articles for article (PubMed ID: 24857864)
1. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.
Wu Z; Todorov I; Li L; Bading JR; Li Z; Nair I; Ishiyama K; Colcher D; Conti PE; Fraser SE; Shively JE; Kandeel F
Bioconjug Chem; 2011 Aug; 22(8):1587-94. PubMed ID: 21692471
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
4. Species differences in pancreatic binding of DO3A-VS-Cys
Eriksson O; Rosenström U; Selvaraju RK; Eriksson B; Velikyan I
Acta Diabetol; 2017 Nov; 54(11):1039-1045. PubMed ID: 28891030
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
[TBL] [Abstract][Full Text] [Related]
6. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
[TBL] [Abstract][Full Text] [Related]
7. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
8. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets.
Wu Z; Liu S; Hassink M; Nair I; Park R; Li L; Todorov I; Fox JM; Li Z; Shively JE; Conti PS; Kandeel F
J Nucl Med; 2013 Feb; 54(2):244-51. PubMed ID: 23297075
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of [
Li J; Rawson J; Chea J; Tang W; Miao L; Sui F; Li L; Poku E; Shively JE; Kandeel F
Sci Rep; 2019 Apr; 9(1):5705. PubMed ID: 30952975
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
Mi B; Xu Y; Pan D; Wang L; Yang R; Yu C; Wan W; Wu Y; Yang M
Biochem Biophys Res Commun; 2016 Feb; 471(1):47-51. PubMed ID: 26850848
[TBL] [Abstract][Full Text] [Related]
15. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
16. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs.
Nalin L; Selvaraju RK; Velikyan I; Berglund M; Andréasson S; Wikstrand A; Rydén A; Lubberink M; Kandeel F; Nyman G; Korsgren O; Eriksson O; Jensen-Waern M
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1800-10. PubMed ID: 24643781
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
19. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
20. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
